Filing Flows › Kyntra Bio (KYNB) › Q1 2026
Kyntra Bio (KYNB) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Kyntra Bio (KYNB) reported revenue of $3.7M for the first quarter 2026 (Q1 2026), +36% from a year earlier and +193% from the quarter before. Operating margin was -369.7%, net loss $15.2M (406.6% of revenue).
Kyntra Bio, Q1 2026: revenue $3.7M (+36% year over year), operating margin -369.7%, net loss $15.2M, operating cash flow −$13.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.7M | +193% | +36% |
| Operating profit | −$13.8M | — | — |
| Net earnings | −$15.2M | — | -428% |
| Operating cash flow | −$13.9M | — | -611% |
What changed
Revenue was $3.7M in Q1 2026, up 36% year over year and up 193% from the previous quarter. Drug Product Revenue was the largest line at 93% of revenue. Drug Product Revenue added $897K year over year (up 35%), 90% of the total change.
Operating costs exceeded revenue by $13.8M, an operating margin of -369.7%. Total costs fell 1% while revenue rose 36%. The fastest-growing cost line was Cost of revenue (+1529%). The quarter ended with a net loss of $15.2M, wider than the previous quarter's $14.2M loss.
Operating cash flow was −$13.9M. Non-cash charges added back $1.2M of share-based compensation.
Questions
What was Kyntra Bio's revenue in the first quarter 2026?
Kyntra Bio (KYNB) reported revenue of $3.7M for the first quarter 2026 (Q1 2026), +36% from a year earlier and +193% from the quarter before.
Was Kyntra Bio profitable in the first quarter 2026?
Operating loss was $13.8M (-369.7% of revenue) and net loss $15.2M.
Source: Kyntra Bio 10-Q on SEC EDGAR.